// App-Quantinova.ai

P086 : Effectiveness of Lymphocyte-Based Re-Treatment Criteria in Minimizing the Incidence of Severe Sustained Lymphopenia with Cladribine Tablets 3.5 mg/kg

Researchers

Presenter

  • Fernando Dangond

Principal Investigators

  • Stuart Cook

  • Giancarlo Comi

  • Gavin Giovannoni

  • Peter Rieckmann

  • Per Soelberg-Sorensen

  • Patrick Vermersch

  • Ms. Christine Hicking

Medical Centers

  • The State University of New Jersy, New Brunswick, NJ

  • Universita Vita Salute San Raffaele, Milan, Italy

  • Queen Mary University of London, William Harvey Research Institute, London, United Kingdom

  • Akademisches Krankenhaus Sozialstiftung Bamberg, Bamberg, Germany

  • 2Danish Multiple Sclerosis Registry, Copenhagen University Hospital København Ø Denmark

  • Universite de Lille 3, Lille, France

  • EMD Serono, Inc, Billerica, MA

  • Merck KGaA, Darmstadt, Germany

Locations

  • United States

  • Italy

  • United Kingdom

  • Germany

  • Denmark

  • France

Companies

  • EMD Serono Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lymphocytopenia

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Cladribine

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved